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Introduction	  	   “Pain	  is	  a	  more	  terrible	  lord	  of	  mankind	  than	  even	  death	  itself.”	  Dr.	  Albert	  Schweitzer	  made	  this	  statement	  in	  1931,	  and	  many	  in	  the	  medical	  community	  would	  argue	  that	  it	  still	  holds	  true	  today.	  According	  to	  the	  National	  Institutes	  of	  Health,	  pain	  affects	  more	  people	  than	  diabetes,	  heart	  disease,	  and	  cancer	  combined,	  and	  it	  is	  the	  number	  one	  reason	  why	  Americans	  seek	  health	  care	  treatment	  (NIH,	  2013).	  Over	  100	  million	  Americans	  suffer	  from	  chronic	  pain,	  and	  it	  accounts	  for	  between	  $560	  billion	  to	  $635	  billion	  annually	  in	  American	  health	  care	  costs	  (American	  Academy	  of	  Pain	  Medicine,	  2015).	  	  A	  2006	  survey	  of	  patients	  with	  chronic	  pain	  found	  that	  51%	  felt	  they	  had	  little	  or	  no	  control	  over	  their	  pain,	  which	  makes	  pain	  management	  a	  very	  problematic	  issue	  (AAPM,	  2015).	  	  	   While	  pain	  treatment	  has	  long	  been	  in	  the	  research,	  pain	  management	  in	  systemic	  sclerosis	  has	  not.	  Systemic	  sclerosis,	  or	  scleroderma,	  (SSc)	  occurs	  with	  a	  prevalence	  of	  approximately	  240	  cases	  per	  million	  people	  in	  the	  world,	  with	  an	  incidence	  rate	  of	  20	  per	  million	  (Nikpour,	  Stevens,	  Herrick,	  &	  Proudman,	  2010).	  	  A	  rare,	  rheumatic	  disease	  of	  unknown	  etiology,	  scleroderma	  is	  often	  misdiagnosed,	  with	  many	  of	  its	  symptoms	  going	  untreated.	  SSc	  is	  an	  autoimmune,	  connective	  tissue	  disease,	  marked	  by	  chronic	  hardening	  of	  the	  skin.	  There	  are	  two	  main	  types	  of	  systemic	  sclerosis,	  limited	  and	  diffuse	  (Stisi	  et	  al.,	  2014).	  Limited	  scleroderma	  is	  mainly	  bound	  to	  the	  skin,	  affecting	  the	  face,	  hands,	  and	  fingers.	  Diffuse	  can	  affect	  every	  organ	  in	  the	  body,	  causing	  fibrosis	  of	  lung	  tissue,	  heart	  tissue,	  esophageal	  changes,	  kidney	  damage,	  and	  more.	  In	  both	  forms,	  the	  skin	  loses	  its	  elastin	  and	  becomes	  fibrotic,	  with	  the	  fingers	  contracting	  into	  claw-­‐like	  shapes.	  Painful	  ulcers	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often	  form	  on	  the	  fingertips	  and	  at	  the	  site	  of	  any	  bony	  protuberance.	  Tendon	  friction	  rubs,	  foot	  ulcers,	  and	  musculoskeletal	  pain	  are	  also	  common	  traits,	  as	  is	  Raynaud’s	  phenomenon.	  Patients	  with	  scleroderma,	  especially	  the	  diffuse	  form,	  experience	  pain	  from	  a	  multitude	  of	  sites	  (Shah	  &	  Wigley,	  2013).	  Given	  that	  life	  expectancy	  with	  the	  disease	  is	  approximately	  eleven	  years,	  and	  given	  that	  in	  most	  cases,	  especially	  with	  diffuse	  scleroderma,	  the	  disease	  is	  progressive,	  these	  patients	  spend	  nearly	  a	  decade	  of	  their	  lives	  in	  ever-­‐worsening	  pain	  (Stisis	  et	  al.,	  2014).	  	   Unlike	  with	  the	  treatment	  of	  other	  rheumatic	  conditions	  with	  chronic	  pain,	  such	  as	  rheumatoid	  arthritis	  or	  fibromyalgia,	  pain	  is	  not	  currently	  a	  diagnostic	  criterion	  for	  systemic	  sclerosis,	  and,	  in	  fact,	  little	  is	  actually	  known	  about	  the	  quantity	  and	  quality	  of	  pain	  present	  with	  this	  disease.	  While	  there	  is	  currently	  scant	  literature	  on	  the	  subject	  of	  pain	  control	  in	  SSc,	  what	  is	  out	  there	  demonstrates	  a	  knowledge	  gap	  with	  how	  to	  effectively	  treat	  the	  chronic	  multifocal	  pain	  from	  this	  disease.	  The	  purpose	  of	  this	  paper	  is	  to	  examine	  a	  case	  study	  of	  a	  person	  who	  had	  diffuse	  systemic	  scleroderma	  for	  11	  years,	  until	  her	  death	  from	  the	  disease	  at	  age	  61,	  and	  to	  look	  at	  the	  course	  of	  her	  pain	  experience	  and	  treatment	  for	  that	  pain.	  A	  review	  of	  the	  current	  literature	  will	  be	  conducted	  to	  determine	  the	  barriers	  to	  effective	  pain	  treatment	  for	  SSc.	  The	  most	  appropriate	  treatments	  will	  be	  discussed,	  and	  suggestions	  will	  be	  made	  for	  how	  to	  best	  move	  forward	  with	  pain	  management	  for	  people	  suffering	  from	  this	  debilitating	  disease.	  
Case	  Study	  	   Theresa	  first	  began	  experiencing	  SSc	  symptoms	  at	  the	  age	  of	  51.	  She	  had	  a	  tingling	  pain	  bilaterally	  in	  her	  upper	  extremities	  that	  was	  not	  related	  to	  exercise,	  a	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musculoskeletal	  issue,	  or	  any	  other	  known	  source.	  She	  sought	  medical	  care	  for	  the	  issue,	  and	  received	  a	  diagnosis	  of	  Reynaud’s	  phenomenon.	  	  A	  few	  months	  later,	  Theresa	  began	  noticing	  her	  mouth	  was	  dry,	  and	  her	  eyes	  were	  red	  and	  irritated.	  Again	  she	  sought	  medical	  advice,	  and	  was	  diagnosed	  with	  Sjogren’s	  syndrome.	  Approximately	  a	  year	  later,	  she	  began	  experiencing	  other	  symptoms:	  pain	  of	  unknown	  origin,	  tightening	  of	  the	  skin	  on	  her	  hands,	  acid	  reflux,	  and	  more.	  She	  sought	  help	  from	  a	  family	  practitioner	  who	  referred	  Theresa	  to	  a	  rheumatologist.	  	  The	  rheumatologist	  treated	  Theresa	  for	  Reynaud’s	  phenomenon	  (RP)	  and	  Sjogren’s	  syndrome	  for	  two	  years,	  and	  she	  had	  little	  improvement	  in	  symptoms.	  Both	  RP	  and	  Sjogren’s	  are	  often	  comorbid	  with	  scleroderma,	  and	  are	  usually	  the	  first	  warning	  signs	  of	  the	  disease.	  Since	  scleroderma	  is	  a	  rare	  condition,	  Theresa	  was	  the	  first	  person	  with	  SSc	  that	  her	  rheumatologist	  had	  ever	  seen.	  Therefore,	  she	  was	  not	  diagnosed	  with	  SSc	  for	  another	  two	  years,	  and	  thus,	  did	  not	  receive	  medication	  (Cellcept)	  that	  could	  have	  slowed	  the	  progression	  of	  her	  disease.	  	   After	  receiving	  a	  referral	  to	  another	  rheumatologist,	  Theresa	  was	  diagnosed	  as	  having	  systemic	  sclerosis,	  a	  progressive	  autoimmune	  and	  connective	  tissue	  disease,	  with	  a	  10-­‐year	  prognosis.	  Her	  disease	  followed	  the	  expected	  progression	  track,	  beginning	  with	  sclerodactyly	  (skin	  thickening	  and	  hand	  contractures),	  followed	  by	  ulceration	  of	  her	  joints	  due	  to	  calcinosis,	  later	  to	  be	  accompanied	  by	  esophageal	  constricture	  causing	  severe	  acid	  reflux	  and	  aspiration.	  Soon	  after,	  Theresa’s	  lungs	  became	  involved,	  with	  scar	  tissue	  developing	  around	  them,	  constricting	  her	  breathing.	  Due	  to	  the	  immunosuppressive	  aspect	  of	  SSc,	  Theresa	  was	  susceptible	  to	  a	  variety	  of	  diseases,	  and	  she	  often	  acquired	  them:	  fighting	  off	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MRSA	  in	  her	  ulcers,	  Escherichia	  coli	  that	  caused	  sepsis,	  and	  eventually	  Clostridium	  difficile,	  which	  is	  what	  finally	  ended	  her	  life,	  although	  the	  official	  cause	  of	  death	  was	  malnutrition.	  	   Throughout	  her	  11-­‐year	  fight	  against	  this	  debilitating	  disease,	  the	  biggest	  battle	  Theresa	  fought	  was	  against	  the	  never-­‐ending	  pain	  that	  affected	  nearly	  every	  part	  of	  her	  body.	  The	  ulcers	  and	  hand	  contractures	  caused	  severe	  pain,	  and	  she	  spent	  nearly	  two	  hours	  a	  day	  bandaging	  the	  open	  wounds.	  Weeks	  were	  spent	  shopping	  for	  bed	  sheets	  that	  did	  not	  hurt	  her	  while	  she	  attempted	  to	  sleep.	  The	  head	  of	  her	  bed	  had	  to	  be	  elevated	  to	  help	  with	  the	  constant	  acid	  reflux.	  Walking	  became	  nearly	  impossible	  because	  of	  the	  ulcers	  on	  her	  toes	  and	  heels,	  and	  the	  tendon	  friction	  rubs	  and	  musculoskeletal	  pain	  often	  left	  her	  immobile.	  	  	   Theresa	  once	  sought	  help	  from	  the	  local	  pain	  management	  clinic,	  but	  they	  refused	  to	  manage	  her	  care,	  stating	  they	  did	  not	  work	  with	  scleroderma	  patients	  because	  the	  pain	  was	  untreatable.	  Her	  rheumatologist	  later	  explained	  to	  Theresa	  that	  due	  to	  the	  pain	  in	  SSc	  stemming	  from	  a	  multitude	  of	  locations	  and	  causalities,	  it	  was	  challenging	  to	  provide	  consistent,	  long-­‐term	  treatment,	  which	  was	  the	  reason	  for	  the	  clinic’s	  refusal.	  	   Fairly	  early	  on	  in	  her	  diagnosis,	  Theresa	  was	  prescribed	  an	  antidepressant,	  due	  to	  having	  to	  deal	  with	  a	  terminal	  diagnosis	  and	  the	  unique	  issues	  presented	  by	  this	  disease.	  After	  having	  been	  on	  this	  drug	  for	  several	  years,	  it	  was	  discovered	  that	  the	  medication	  was	  causing	  serious,	  unwanted	  side	  effects,	  such	  as	  uncontrollable	  crying	  and	  severe	  malaise.	  However,	  due	  to	  the	  fact	  that	  Theresa’s	  psychological	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status	  was	  never	  revaluated	  during	  the	  course	  of	  her	  treatment,	  she	  suffered	  with	  these	  issues	  for	  several	  years.	  	  	   Toward	  the	  end	  of	  her	  life,	  Theresa	  was	  in	  a	  motor	  vehicle	  accident	  where	  her	  car	  was	  hit	  by	  a	  van.	  The	  result	  was	  a	  tibular	  plateau	  fracture,	  which	  is	  painful	  in	  and	  of	  itself,	  but	  due	  to	  the	  fibrosis	  around	  her	  knees,	  her	  skin	  was	  unable	  to	  expand	  to	  allow	  for	  the	  swelling;	  so,	  instead,	  the	  blood	  and	  fluid	  were	  pushed	  inward.	  Each	  heartbeat	  resulted	  in	  blood	  and	  fluid	  being	  pushed	  into	  the	  fracture,	  resulting	  in	  agonizing	  pain.	  	   The	  nurse	  on	  duty	  in	  the	  emergency	  department	  the	  night	  of	  Theresa’s	  accident	  refused	  to	  give	  Theresa	  the	  necessary	  amount	  of	  analgesic	  needed	  to	  alleviate	  her	  pain.	  Due	  to	  Theresa’s	  small	  stature	  (she	  only	  weighed	  ninety	  pounds)	  the	  nurse	  prescribed	  5	  mg	  of	  morphine.	  Normally,	  Theresa	  was	  prescribed	  80	  mg	  of	  oxycodone	  daily,	  in	  addition	  to	  10/500	  Lortabs	  as	  needed	  (which	  she	  took	  at	  least	  4	  of	  per	  day),	  and	  NSAIDS.	  She	  had	  an	  extremely	  high	  analgesic	  threshold;	  and	  no	  amount	  of	  advocating	  for	  higher	  dosages	  by	  Theresa	  or	  her	  family	  worked	  to	  change	  the	  course	  of	  treatment	  that	  was	  prescribed.	  This	  was	  the	  common	  theme	  throughout	  nearly	  every	  hospitalization	  she	  endured.	  	   During	  the	  last	  hospitalization	  of	  her	  life,	  when	  she	  had	  contracted	  C.	  difficile,	  Theresa	  was	  given	  no	  pain	  medication	  for	  the	  first	  two	  weeks	  of	  her	  hospitalization.	  In	  a	  discussion	  with	  Theresa’s	  primary	  care	  practitioner	  after	  Theresa’s	  death,	  the	  Physicians	  Assistant	  stated	  that	  Theresa	  most	  likely	  went	  into	  withdrawal	  during	  that	  two-­‐week	  period,	  and	  that	  withdrawal	  most	  likely	  factored	  into	  her	  death.	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Pathophysiology	  of	  Scleroderma	  	   Systemic	  sclerosis	  is	  an	  autoimmune,	  connective	  tissue	  disease,	  like	  Multiple	  Sclerosis	  or	  systemic	  lupus.	  However,	  unlike	  these	  other	  diseases,	  very	  little	  is	  known	  about	  the	  pathogenesis	  of	  scleroderma.	  Three	  clinical	  features	  are	  known	  to	  occur	  in	  all	  cases:	  activation	  of	  the	  immune	  system,	  damage	  to	  the	  vascular	  system,	  and	  “excessive	  synthesis	  of	  extracellular	  matrix	  with	  deposition	  of	  increased	  amounts	  of	  structurally	  normal	  collagen”	  (Denton,	  2014,	  para	  1).	  	  This	  collagen	  tends	  to	  build	  up	  under	  the	  skin,	  often	  around	  bony	  prominences	  such	  as	  the	  elbows	  and	  knuckles,	  until	  it	  erupts	  through	  the	  skin	  itself,	  creating	  ulcers,	  that	  are	  then	  susceptible	  to	  infection.	  The	  cardinal	  signs	  of	  the	  disease	  involve	  progressive	  fibrosis	  of	  the	  skin	  and	  the	  internal	  organs,	  the	  latter	  of	  which	  often	  is	  the	  cause	  of	  death	  in	  these	  patients	  (Denton,	  2014).	  	  	   Scleroderma	  is	  a	  multisystem	  disease,	  which	  involves,	  as	  mentioned,	  not	  only	  the	  skin,	  but	  also	  the	  esophagus,	  the	  lungs,	  the	  heart,	  and	  the	  body’s	  connective	  tissues.	  Pain	  associated	  with	  scleroderma	  is	  also	  multifocal	  in	  nature.	  One	  of	  the	  first	  signs	  of	  the	  disease	  is	  the	  comorbid	  diagnosis	  of	  Raynaud’s	  phenomenon,	  often	  followed	  by	  Sjogren’s	  syndrome.	  Both	  diseases	  come	  with	  their	  own	  particular	  manifestations	  of	  pain	  and	  discomfort.	  Additionally,	  patients	  with	  systemic	  sclerosis	  experience	  contractures	  of	  the	  hands,	  swelling	  of	  the	  fingers	  and	  joints,	  thickening	  of	  the	  skin,	  loss	  of	  the	  tips	  of	  the	  fingers,	  calcinosis	  cutis	  of	  the	  hands,	  elbows,	  knees,	  and	  feet,	  tendon	  friction	  rubs,	  tightening	  around	  the	  mouth	  which	  can	  result	  in	  constriction	  of	  the	  oral	  aperture,	  mucocutaneous	  telangiectasias,	  and	  many	  other	  physical	  symptoms	  (Varga,	  2014).	  	  Esophageal	  involvement	  leads	  to	  heartburn,	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aspiration,	  and	  dysphagia	  (Varga,	  2014).	  Multi-­‐organ	  involvement	  causes	  hypertension	  and	  renal	  insufficiency,	  dyspnea,	  and	  gastro-­‐intestinal	  issues,	  such	  as	  diarrhea	  with	  malabsorption	  (Varga,	  2014).	  Due	  to	  the	  pervasiveness	  of	  this	  disease,	  patients	  with	  scleroderma	  endure	  unceasing	  pain	  of	  varied	  types	  throughout	  their	  body.	  	  
Review	  of	  the	  Literature	  Pain	  in	  Systemic	  Sclerosis	  	   People	  with	  rare,	  chronic	  diseases	  are	  at	  risk	  for	  disparity	  in	  the	  literature.	  In	  a	  society	  that	  is	  placing	  increasing	  emphasis	  on	  patient-­‐centered	  care,	  these	  people	  are	  still	  finding	  themselves	  absent	  from	  the	  conversation.	  A	  literature	  search	  of	  Pubmed,	  Cinahl,	  Embase,	  and	  Google	  Scholar,	  using	  the	  search	  terms	  scleroderma,	  
systemic	  sclerosis,	  pain,	  and	  adult,	  from	  the	  years	  2009-­‐2015,	  only	  produced	  11	  articles	  that	  specifically	  looked	  at	  pain	  in	  this	  disease.	  One	  theme	  that	  ran	  throughout	  the	  literature	  on	  systemic	  sclerosis	  was	  a	  lack	  of	  evidenced-­‐based	  interventions	  for	  psychosocial	  and	  rehabilitative	  treatments	  that	  were	  specific	  to	  scleroderma	  (Kwakkenbos	  et	  al.,	  2013).	  	  Barriers	  to	  interventions	  included	  the	  relatively	  small	  number	  of	  people	  living	  with	  this	  disease,	  and	  that	  organizations	  performing	  clinical	  trials	  tend	  to	  focus	  on	  pharmacological	  treatment	  of	  primary	  disease	  (Kwakkenbos	  et	  al.,	  2013).	  The	  latter	  is	  challenging	  for	  SSc,	  since	  the	  etiology	  is	  still	  unknown,	  pharmacological	  treatment	  is	  aimed	  at	  relief	  of	  symptoms.	  Thus	  it	  is	  difficult	  to	  create	  a	  pharmacological	  treatment	  for	  the	  disease	  as	  a	  whole.	  Simultaneously,	  it	  was	  determined	  that	  the	  direct	  and	  indirect	  costs	  of	  this	  disease	  in	  the	  United	  States	  in	  1997	  were	  $1.5	  billion	  (Alcacer-­‐Pitarch	  et	  al.,	  2012).	  	  While	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this	  may	  seem	  minute	  compared	  to	  the	  nearly	  $4	  trillion	  spent	  on	  health	  care	  in	  the	  US	  in	  2014,	  it	  is	  still	  worthy	  of	  note	  when	  looking	  at	  ways	  to	  decrease	  health	  care	  expenditures.	  	   Of	  the	  few	  randomized	  control	  studies	  that	  have	  been	  done	  on	  health	  problems	  faced	  by	  those	  with	  SSc,	  all	  agreed	  that	  pain	  is	  nearly	  ubiquitous	  for	  people	  fighting	  this	  disease	  (Kallen	  et	  al.,	  2010).	  In	  a	  descriptive	  study	  of	  484	  patients	  with	  scleroderma,	  83%	  of	  patients	  reported	  experiencing	  pain,	  with	  37%	  stating	  their	  pain	  quality	  to	  be	  moderate	  to	  severe	  (Schieir	  et	  al,	  2010).	  Other	  studies	  found	  the	  range	  of	  patients	  with	  pain	  symptoms	  to	  be	  between	  60%	  and	  83%	  (Chularojanamontri	  et	  al.,	  2011).	  	  Patients	  with	  rheumatic	  diseases	  have	  stated	  that	  the	  need	  for	  improving	  their	  ability	  to	  manage	  their	  pain	  is	  their	  number	  one	  priority	  (Schieir	  et	  al.,	  2010).	  	  	   Kallen	  et	  al.	  used	  a	  modified	  version	  of	  the	  Symptom	  Burden	  Index	  to	  determine	  the	  problems	  perceived	  by	  people	  with	  SSc,	  and	  to	  quantify	  those	  problems	  as	  they	  related	  to	  the	  daily	  functioning	  of	  these	  patients	  (Kallen	  et	  al.,	  2010).	  They	  found	  that	  there	  are	  a	  wide	  variety	  of	  symptoms	  and	  impairments	  to	  daily	  functioning	  experienced	  by	  people	  with	  SSc,	  with	  depression	  and	  disablement	  related	  to	  the	  disease	  being	  two	  of	  the	  major	  issues	  contributing	  to	  decreased	  quality	  of	  life	  (Kallen	  et	  al.,	  2010).	  While	  their	  sample	  size	  was	  only	  62	  patients,	  they	  found	  pain	  to	  be	  the	  problem	  ranked	  as	  the	  highest	  average	  burden	  by	  their	  study	  sample	  (Kallen	  et	  al.,	  2010).	  Pain	  was	  also	  ranked	  as	  one	  of	  four	  burdens	  with	  the	  highest	  frequency	  (the	  others	  being	  bowel,	  eating,	  and	  skin-­‐	  all	  of	  which	  present	  their	  own	  pain	  issues)	  (Kallen	  et	  al.,	  2010).	  These	  results	  indicate	  that	  pain	  causes	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the	  greatest	  amount	  of	  burden	  to	  people	  living	  with	  this	  disease	  (Kallen	  et	  al.,	  2010).	  Of	  additional	  note	  from	  this	  study,	  64%	  of	  the	  sampled	  population	  reported	  experiencing	  6	  or	  more	  SSc-­‐related	  problems	  simultaneously,	  36%	  reported	  experiencing	  7	  to	  8	  problems,	  and	  18%	  had	  all	  8	  problems	  being	  tested	  for	  in	  the	  study	  (Kallen	  et	  al.,	  2010).	  	  The	  results	  from	  this	  study	  suggest	  that	  pain	  management	  should	  be	  a	  priority	  for	  these	  patients	  as	  the	  multi-­‐focal	  chronic	  nature	  of	  this	  disease	  leaves	  patient’s	  energy	  reserve	  depleted	  and	  their	  psychosocial	  systems	  strained.	  	   However,	  despite	  pain	  having	  a	  front	  row	  seat	  in	  the	  complex	  play	  of	  this	  disease,	  very	  little	  has	  been	  written	  about	  it	  in	  the	  literature.	  As	  of	  2010,	  when	  Schieir	  et	  al.	  published	  their	  study,	  only	  3	  other	  studies	  had	  been	  conducted	  to	  determine	  the	  occurrence	  of	  pain	  in	  SSc	  (Schieir	  et	  al,	  2010).	  Schieir	  et	  al.	  conjectured	  that	  the	  limited	  research	  into	  this	  area,	  which	  has	  been	  found	  in	  approximately	  two-­‐thirds	  of	  those	  who	  suffer	  from	  SSc,	  might	  be	  due	  to	  pain	  in	  SSc	  being	  assessed	  and	  treated	  less	  often	  by	  clinicians	  than	  pain	  from	  other	  rheumatic	  diseases	  such	  as	  rheumatoid	  arthritis	  (Schieir	  et	  al,	  2010).	  	  The	  team	  cited	  a	  study	  that	  suggested	  that	  a	  10-­‐	  20%	  change	  in	  pain	  management	  for	  the	  patients	  would	  correlate	  to	  a	  “clinically	  meaningful	  difference”	  (Schieir	  et	  al,	  2010).	  	   Then	  why	  is	  this	  not	  occurring?	  Why	  are	  people	  with	  systemic	  sclerosis	  not	  being	  treated	  for	  their	  pain?	  In	  a	  study	  of	  how	  health	  care	  is	  delivered	  to	  patients	  with	  SSc,	  the	  patients	  stated	  that	  their	  pain	  needs	  were	  not	  being	  sufficiently	  addressed	  by	  their	  rheumatologists	  (Schouffoer	  et	  al,	  2010).	  	  Another	  study,	  conducted	  just	  last	  year,	  found	  that	  in	  a	  sample	  size	  of	  333	  people	  with	  systemic	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sclerosis,	  190	  were	  not	  taking	  any	  pain	  medication	  at	  all	  (Merz	  et	  al.,	  2014).	  Due	  to	  the	  rarity	  of	  the	  disease,	  there	  is	  a	  serious	  lack	  of	  research	  into	  this	  area	  (Schouffoer	  et	  al,	  2010).	  	  	   	  Scleroderma	  pain	  is	  multifocal,	  and	  often	  comes	  from	  unknown	  sources,	  therefore	  making	  it	  very	  challenging	  to	  treat.	  	  In	  addition	  to	  the	  physical	  pain	  from	  the	  disease,	  psychosocial	  issues	  are	  also	  present.	  Depression	  has	  been	  linked	  in	  the	  literature	  to	  pain,	  and	  has	  a	  strong	  prevalence	  in	  SSc;	  one	  that	  is	  often	  overlooked.	  Additionally,	  to	  being	  able	  to	  adequately	  treat	  pain,	  pain	  needs	  to	  be	  effectively	  assessed,	  and	  this	  is	  not	  currently	  being	  done	  as	  standard	  practice	  with	  patients	  with	  SSc.	  Lastly,	  the	  available	  methods	  for	  management	  of	  pain	  from	  systemic	  sclerosis	  are	  scarce,	  and	  little	  is	  known	  about	  the	  most	  effective	  ways	  to	  provide	  this	  much	  needed	  service.	   Types	  of	  Pain	  in	  Systemic	  Sclerosis	  	   One	  of	  the	  biggest	  barriers	  to	  pain	  management	  in	  Scleroderma	  is	  the	  fact	  that	  the	  symptomatic	  pain	  is	  multifocal.	  Physical	  emanations	  of	  pain	  come	  from	  a	  myriad	  of	  sources.	  According	  to	  research,	  pain	  from	  digital	  ulcers,	  which	  are	  experienced	  by	  30	  to	  50%	  of	  SSc	  patients,	  significantly	  affects	  their	  quality	  of	  life	  (Rosato	  et	  al.,	  2009).	  These	  digital	  ulcers	  can	  also	  lead	  to	  infections,	  osteomyelitis,	  and	  eventually	  amputation,	  all	  of	  which	  are	  extremely	  painful	  processes	  (Rosato	  et	  al.,	  2009).	  	  In	  conjunction	  with	  the	  digital	  ulcers,	  Raynaud’s	  phenomenon	  (RP)	  is	  another	  cause	  of	  significant	  pain	  in	  SSc.	  The	  hallmark	  of	  RP	  in	  scleroderma	  is	  severe,	  painful,	  unilateral	  attacks	  of	  the	  extremities	  leading	  to	  ischemic	  skin	  lesions	  (digital	  ulcers)	  (Rosato	  et	  al.,	  2009).	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   Musculoskeletal	  pain	  is	  another	  source	  experienced	  by	  SSc	  patients.	  Tendon	  friction	  rubs	  are	  common	  and	  very	  painful	  (Sstisi	  et	  al.,	  2014).	  Other	  types	  of	  musculoskeletal	  pain	  noted	  in	  SSc	  include	  polyarthritis	  in	  36-­‐	  80%	  of	  patients,	  Rheumatoid	  arthritis,	  and	  chronic	  widespread	  pain	  in	  27.1%	  of	  patients	  (Sstisi	  et	  al.,	  2014).	  The	  fibrotic	  process	  of	  SSc	  can	  cause	  joints	  and	  tendons	  to	  become	  entrapped,	  leading	  to	  contractures	  and	  tendon	  friction	  rubs,	  all	  of	  which	  are	  painful	  processes	  (Shah	  &	  Wigley,	  2013).	  	  	   Gastrointestinal	  impairment	  is	  also	  a	  major	  source	  of	  pain	  and	  decreased	  quality	  of	  life	  for	  people	  with	  scleroderma.	  For	  patients	  whose	  skin	  is	  affected,	  the	  skin	  around	  the	  mouth	  will	  contract;	  causing	  a	  decreased	  oral	  aperture	  that	  can	  be	  painful	  when	  eating	  (Shah	  &	  Wigley,	  2013).	  Sjogren’s	  syndrome,	  another	  common	  comorbidity	  with	  SSc,	  can	  cause	  deficient	  saliva,	  leading	  to	  tooth	  decay	  and	  pain	  on	  chewing	  (Shah	  &	  Wigley,	  2013).	  	  According	  to	  Shah	  &	  Wigley,	  the	  most	  commonly	  occurring	  problem	  in	  all	  subsets	  of	  systemic	  sclerosis	  is	  esophageal	  dysfunction	  (Shah	  &	  Wigley,	  2013).	  	  Issues	  with	  the	  functioning	  of	  the	  esophagus	  lead	  to	  heartburn,	  regurgitation	  (and	  possible	  aspiration),	  and/or	  dysphagia	  (Shah	  &	  Wigley,	  2013).	  	  GERD	  can	  then	  lead	  to	  esophagitis,	  bleeding,	  strictures,	  and	  possible	  formation	  of	  Barrett’s	  esophagus	  (Shah	  &	  Wigley,	  2013).	  Due	  to	  intermittent	  bouts	  of	  pseudo-­‐obstruction,	  SSc	  patients	  commonly	  experience	  bloating,	  diarrhea,	  and/or	  constipation,	  and	  are	  prone	  to	  such	  infections	  as	  Clostridium	  difficile	  (Shah	  &	  Wigley,	  2013).	  	  Nearly	  all	  of	  these	  issues	  are	  painful,	  or	  will	  lead	  to	  other	  painful,	  chronic	  conditions.	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   Other	  physical	  issues	  contributing	  to	  the	  pain	  profile	  include:	  foot	  pain	  (from	  plantar	  pressure	  and	  ulcers	  on	  the	  feet),	  calcinosis	  (which	  ranked	  extremely	  high	  on	  several	  pain	  studies),	  microstomia,	  xerostomia,	  autoimmune	  hepatitis,	  vaginal	  dryness,	  and	  neuropathy.	  In	  a	  2013	  study	  by	  Perrot	  et	  al.,	  43.6%	  of	  patients	  with	  SSc	  reported	  neuropathic	  pain	  (Perrot	  et	  al.,	  2013).	  Prior	  to	  this	  study,	  very	  little	  had	  been	  known	  about	  the	  presence	  of	  neuropathic	  pain	  in	  SSc	  (Perrot	  et	  al.,	  2013).	  Pain	  and	  Depression	  	   According	  to	  Shieir	  et	  al.,	  pain	  in	  scleroderma	  is	  a	  major	  predictor	  of	  quality	  of	  life	  (Schieir	  et	  al.,	  2010).	  A	  study	  conducted	  in	  2014	  dove	  further	  into	  this	  concept	  to	  look	  at	  what	  comprises	  the	  pain	  experienced	  by	  SSc	  patients.	  Merz	  et	  al.	  posited	  that	  the	  pain	  from	  SSc	  is	  not	  purely	  a	  physical	  pain,	  but	  also	  has	  psychological	  and	  social	  components	  as	  well	  (Merz	  et	  al.,	  2014).	  They	  stated	  that	  the	  primary	  goals	  of	  care	  for	  patients	  with	  this	  disease	  are	  to	  attempt	  to	  preserve	  their	  functional	  abilities	  to	  the	  greatest	  possible	  extent,	  provide	  as	  much	  relief	  from	  their	  symptoms	  as	  is	  feasible,	  and	  to	  increase	  their	  quality	  of	  life	  (Merz	  et	  al.,	  2014).	  To	  accomplish	  these	  goals	  with	  a	  multifocal	  disease	  like	  scleroderma,	  Merz	  et	  al.	  posited	  that	  a	  multifocal	  approach	  is	  needed,	  and	  that	  “pain	  is	  not	  a	  purely	  physical	  phenomenon”	  (Merz	  et	  al.,	  2014).	  Research	  has	  stated	  that	  around	  half	  of	  people	  living	  with	  chronic	  pain	  also	  experience	  depression	  and	  anxiety,	  and	  that	  both	  of	  these	  conditions	  have	  an	  established	  relationship	  with	  pain	  (Merz	  et	  al.,	  2014).	  	  The	  team	  also	  found	  that	  catastrophizing	  about	  the	  progression	  of	  scleroderma,	  something	  that	  is	  fairly	  common	  in	  this	  population,	  had	  a	  direct	  link	  with	  pain	  (Merz	  et	  al.,	  2014).	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   In	  a	  similar	  study	  looking	  at	  the	  link	  between	  depression	  and	  anxiety	  with	  pain,	  Nicholson	  et	  al.	  found	  that	  patients	  with	  depression	  are	  significantly	  more	  likely	  to	  express	  pain	  than	  those	  who	  are	  not	  depressed	  (Nicholson	  et	  al.,	  2009).	  On	  a	  similar	  note,	  patients	  who	  experience	  chronic	  pain	  are	  more	  likely	  to	  also	  have	  depressive	  symptoms	  (Nicholson	  et	  al.,	  2009).	  As	  their	  pain	  worsens,	  so	  does	  their	  depression,	  and	  vice	  versa	  (Nicholson	  et	  al.,	  2009).	  	  	  	   Because	  of	  the	  multitude	  of	  issues	  that	  occur	  as	  a	  result	  of	  scleroderma,	  both	  physically	  and	  emotionally,	  depression	  is	  a	  very	  real	  possibility	  in	  the	  lives	  of	  people	  with	  this	  disease.	  Kwakkenbos	  et	  al.	  found	  that	  32.1%	  of	  SSc	  patients	  were	  experiencing	  depression	  (Kwakkenbos	  et	  al.	  2011).	  Pain	  was	  a	  definitive	  cause	  of	  these	  depressive	  symptoms,	  as	  were	  other,	  non-­‐physical	  factors	  (Kwakkenbos	  et	  al.	  2011).	  Shah	  &	  Wigley	  note	  that	  depression	  is	  almost	  universal	  when	  a	  person	  is	  faced	  with	  all	  of	  the	  manifestations	  of	  this	  disease	  (Shah	  &	  Wigley,	  2014).	  Regardless	  of	  the	  cause,	  depression	  experienced	  by	  people	  with	  SSc	  has	  been	  proven	  to	  lead	  to	  increased	  pain,	  and	  therefore	  needs	  to	  be	  an	  important	  component	  of	  the	  scleroderma	  patient’s	  assessment.	  Assessment	  of	  Pain	  
	   Research	  into	  the	  topic	  of	  pain	  in	  systemic	  sclerosis	  concludes	  that	  pain	  assessment	  during	  both	  the	  initial	  visit	  to	  the	  rheumatologist,	  and	  in	  subsequent	  visits,	  is	  not	  being	  conducted	  appropriately.	  In	  the	  American	  College	  of	  Rheumatology’s	  informational	  booklet	  on	  scleroderma,	  the	  section	  on	  what	  signs	  and	  symptoms	  the	  healthcare	  provider	  may	  assess	  for	  only	  mentions	  joint	  pain,	  as	  the	  last	  bullet	  point	  in	  the	  list	  (Merkel,	  2013).	  Similarly,	  Shah	  &	  Wigley’s	  article,	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written	  by	  two	  of	  the	  most	  preeminent	  clinicians	  in	  the	  study	  of	  this	  disease,	  does	  not	  mention	  pain	  among	  the	  diagnostic	  criterion	  for	  scleroderma	  (Shah	  &	  Wigley,	  2014).	  In	  fact,	  they	  barely	  mention	  pain	  at	  all	  in	  their	  article,	  instead	  stating	  that	  scleroderma	  causes	  “significant	  physical	  distress”	  (Shah	  &	  Wigley,	  2014,	  p.2).	  Pain	  is	  a	  prominent	  factor	  in	  most	  rheumatic	  diseases,	  and	  is	  considered	  to	  be	  the	  main	  symptom	  of	  diseases	  such	  as	  rheumatoid	  arthritis	  and	  osteoarthritis,	  where	  it	  is	  a	  disease	  activity	  biomarker	  (Perrot	  et	  al.,	  2013).	  	  Perrot	  et	  al.	  determined	  that	  the	  results	  of	  their	  study	  comparing	  pain	  in	  systemic	  sclerosis	  to	  pain	  in	  rheumatoid	  arthritis	  showed	  conclusively	  that	  pain	  should	  be	  assessed	  in	  patients	  with	  SSc,	  and	  that	  the	  assessment	  should	  include	  both	  physical	  and	  psychological	  symptoms	  (Perrot	  et	  al.,	  2013).	  	  	   In	  his	  study	  regarding	  how	  pain	  and	  mood	  are	  connected	  in	  rheumatic	  diseases,	  Goldberg	  noted	  that	  formal	  chronic	  pain	  management	  training	  has	  never	  been	  a	  part	  of	  the	  medical	  education	  of	  rheumatologists	  (Goldenberg,	  2010).	  	  The	  fault,	  however,	  does	  not	  lie	  solely	  with	  the	  clinicians	  assessing	  these	  patients.	  The	  manner	  in	  which	  pain	  is	  assessed	  in	  SSc	  patients	  also	  presents	  a	  barrier,	  as	  no	  gold	  standard	  for	  the	  practice	  has	  yet	  been	  developed.	  Several	  trials	  have	  been	  undertaken	  to	  adapt	  such	  assessments	  as	  the	  Health	  Assessment	  Questionnaire	  for	  Rheumatoid	  Arthritis	  and	  the	  Short	  Form	  36,	  but	  no	  definitive	  scale	  has	  yet	  been	  determined	  (Kallen	  et	  al.,	  2010).	  Momeni	  et	  al.,	  in	  their	  study	  of	  surgical	  treatment	  options	  for	  systemic	  sclerosis,	  noted	  a	  need	  for	  standardized	  outcome	  measures	  for	  pain	  so	  as	  to	  help	  advance	  research	  into	  treatments	  (Momenti	  et	  al.,	  2015).	  In	  an	  editorial	  to	  the	  University	  of	  Oxford	  Press	  regarding	  assessing	  pain	  in	  scleroderma,	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Carreira	  agreed	  that	  a	  lack	  of	  consistency	  in	  the	  scales	  and	  tools	  used	  to	  measure	  pain	  in	  this	  disease	  is	  holding	  back	  the	  advancement	  of	  rheumatology	  in	  this	  field,	  as	  well	  as	  causing	  undue	  suffering	  in	  the	  lives	  of	  patients	  with	  systemic	  sclerosis	  (Carreira,	  2006).	   Pain	  Management	  Methods	  	   Compared	  to	  patients	  with	  RA,	  patients	  with	  scleroderma	  find	  their	  pain	  being	  treated	  less	  frequently,	  and	  find	  the	  effects	  of	  those	  treatments	  to	  be	  more	  ineffective	  (Perrot	  et	  al.	  2013).	  Perrot	  et	  al.	  attribute	  this	  lack	  of	  effectiveness	  to	  the	  multicausality	  of	  systemic	  sclerotic	  pain	  (Perrot	  et	  al.	  2013).	  When	  pain	  is	  coming	  from	  a	  variety	  of	  different	  sources,	  in	  a	  number	  of	  different	  manners,	  it	  is	  challenging	  to	  find	  one,	  or	  even	  a	  combination	  of	  treatments	  that	  will	  effectively	  combat	  it.	  	  	   The	  most	  common	  way	  pain	  is	  alleviated	  in	  the	  medical	  world	  is	  through	  pharmacology,	  generally	  with	  the	  use	  of	  analgesic	  medications.	  This	  has	  not	  historically	  been	  the	  case	  with	  scleroderma,	  however.	  	  In	  the	  Merz	  study,	  as	  previously	  mentioned,	  190	  of	  the	  333	  participants	  were	  not	  taking	  any	  pain	  medication	  (Merz	  et	  al.,	  2014).	  Of	  the	  remaining	  149	  patients,	  66	  were	  taking	  acetaminophen/NSAIDS,	  18	  were	  taking	  tramadol,	  and	  59	  were	  taking	  narcotics	  (Merz	  et	  al.,	  2014).	  	  NSAIDS	  and	  tramadol	  are	  the	  current	  standard	  therapy	  for	  pain	  control	  in	  systemic	  sclerosis,	  but	  are	  often	  found	  to	  be	  inadequate	  or	  limited	  in	  dosage	  by	  their	  side	  effects	  (Giuggioli	  et	  al.,	  2010).	  	  Giuggioli	  conducted	  a	  study	  of	  29	  patients,	  for	  a	  mean	  period	  of	  7.9	  +/-­‐	  3.2	  SD	  months,	  to	  evaluate	  the	  efficacy	  of	  treatment	  with	  oxycodone,	  instead	  of	  the	  traditional	  tramadol	  treatment	  (Giuggioli	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et	  al.,	  2010).	  In	  all	  cases,	  the	  respondents	  reported	  their	  pain	  as	  severe,	  according	  to	  World	  Health	  Organization	  guidelines,	  and	  all	  had	  long-­‐standing	  skin	  ulcers	  (Giuggioli	  et	  al.,	  2010).	  The	  patients	  were	  given	  between	  20	  and	  40	  mg	  of	  oxycodone	  cholridate	  daily,	  and	  it	  was	  titrated	  as	  needed	  (Giuggioli	  et	  al.,	  2010).	  At	  the	  end	  of	  the	  first	  month	  of	  therapy,	  all	  patients	  reported	  some	  relief	  of	  pain	  (VAS	  decreased	  from	  93.8	  +/-­‐	  8.72	  to	  56.7	  +/-­‐	  10.4,	  P<0.0001)	  (Giuggioli	  et	  al.,	  2010).	  At	  the	  end	  of	  the	  three-­‐month	  mark,	  again	  all	  respondents	  reported	  a	  decrease	  in	  pain	  (VAS	  decreased	  to	  42.9	  +/-­‐	  14.9)	  (Giuggioli	  et	  al.,	  2010).	  	  No	  patient	  in	  the	  trial	  experienced	  any	  severe	  adverse	  advents,	  and	  of	  particular	  note	  is	  that	  no	  patient	  experienced	  abstinence	  phenomenon	  at	  the	  end	  of	  the	  trial	  (Giuggioli	  et	  al.,	  2010).	  Their	  conclusion	  was	  that	  while	  standardized	  analgesic	  protocols	  do	  not	  yet	  exist	  for	  SSc,	  an	  “aggressive	  therapeutic	  approach”	  is	  required	  to	  manage	  these	  patients’	  pain	  (Giuggioli	  et	  al.,	  2010).	  	   The	  undermedication	  of	  patients	  with	  opioids	  is	  a	  topic	  of	  significant	  research	  in	  the	  literature.	  The	  American	  Academy	  of	  Pain	  Medicine	  released	  an	  informational	  brief	  in	  2013	  providing	  “Statements	  on	  the	  Use	  of	  Opioids	  in	  Chronic	  Pain”,	  meant	  as	  a	  guideline	  for	  physicians	  in	  prescribing	  medications	  like	  Oxycontin	  to	  patients	  with	  chronic	  pain	  conditions	  (American	  Academy	  of	  Pain	  Medicine,	  2013).	  These	  statements	  include	  one	  that	  notes	  that,	  while	  it	  is	  important	  to	  consider	  the	  risks	  of	  addiction	  and	  tolerance,	  many	  commonly	  held	  assumptions	  about	  these	  dangers	  are	  unfounded	  (American	  Academy	  of	  Pain	  Medicine,	  2013).	  	  The	  Academy	  cautioned	  against	  assuming	  someone	  is	  an	  addict,	  and	  noted	  the	  importance	  of	  weighing	  fears	  about	  addiction	  with	  the	  need	  for	  pain	  relief	  in	  these	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patients	  (American	  Academy	  of	  Pain	  Medicine,	  2013).	  It	  goes	  on	  to	  state	  that	  the	  previously	  held	  belief	  that	  developing	  tolerance	  to	  an	  analgesic	  meant	  the	  opioid	  would	  no	  longer	  be	  effective	  in	  the	  long-­‐term	  is	  false	  (American	  Academy	  of	  Pain	  Medicine,	  2013).	  Additionally,	  the	  statement	  pointed	  out	  that	  what	  initially	  looked	  like	  the	  development	  of	  tolerance	  in	  those	  patients	  tested	  was	  actually	  the	  natural	  progression	  of	  the	  disease	  state	  (American	  Academy	  of	  Pain	  Medicine,	  2013).	  This	  is	  important	  and	  useful	  information	  for	  rheumatologists	  and	  other	  clinicians	  treating	  patients	  with	  SSc,	  as	  concerns	  about	  the	  potential	  for	  abuse	  and	  addiction,	  long-­‐term	  and	  short-­‐term	  side	  effects,	  and	  outcomes	  all	  continue	  to	  hinder	  health	  care	  professionals	  from	  adequately	  prescribing	  opioids	  for	  chronic	  pain	  management	  (Rosenblum	  et	  al.,	  2008).	  	   Non-­‐opioid	  pharmacological	  treatments	  for	  pain	  in	  SSc	  have	  also	  been	  posited.	  	  Nicholson	  et	  al.	  looked	  at	  the	  possibility	  of	  using	  tricyclic	  antidepressants	  (TCA’s)	  as	  a	  means	  of	  combating	  both	  the	  pain	  of	  rheumatic	  disorders	  and	  their	  psychological	  effects	  (Nicholson	  et	  al.,	  2009).	  Serotonin	  and	  norephinephrine	  reuptake	  inhibitors	  (SNRI’s)	  were	  also	  discussed,	  as	  the	  produce	  fewer	  anticholinergic	  effects	  than	  do	  TCA’s,	  which	  would	  be	  particularly	  beneficial	  in	  someone	  experiencing	  Sjogren’s	  syndrome,	  as	  is	  so	  often	  common	  in	  SSc	  patients	  (Nicholson	  et	  al.,	  2009).	  They	  found	  that	  antidepressants	  were	  most	  effective	  in	  those	  patients	  experiencing	  neuropathic	  pain,	  which	  many	  people	  with	  scleroderma	  do	  (Nicholson	  et	  al.,	  2009).	  	  	   It	  should	  be	  noted	  that	  Nicholson	  et	  al.	  also	  looked	  at	  the	  use	  of	  opioids,	  particularly	  oxycodone,	  in	  the	  treatment	  of	  chronic	  pain,	  and	  found	  that	  most	  of	  the	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research	  conducted	  on	  this	  treatment	  only	  lasted	  eight	  weeks	  or	  less	  (Nicholson	  et	  al.,	  2009).	  The	  above-­‐mentioned	  Giuggioli	  et	  al.	  study	  lasted	  slightly	  longer,	  but	  was	  still	  a	  short-­‐term	  study.	  More	  research	  needs	  to	  be	  conducted	  into	  the	  long-­‐term	  effects	  of	  opioid	  use	  on	  patients	  with	  systemic	  sclerosis	  (Nicholson	  et	  al.,	  2009).	  	   Non-­‐pharmacological	  and	  alternative	  therapies	  have	  also	  been	  researched	  as	  a	  means	  of	  treating	  scleroderma	  pain.	  	  Physical	  therapy,	  particularly	  hand	  therapy,	  should	  be	  started	  as	  early	  as	  possible	  in	  the	  disease	  process,	  as	  it	  will	  improve	  quality	  of	  life	  as	  the	  disease	  progresses	  (Shah	  &	  Wigley,	  2013).	  	  Occupational	  therapy	  can	  also	  be	  helpful	  in	  assisting	  patients	  with	  developing	  skills	  and	  tools	  to	  utilize	  with	  their	  activities	  of	  daily	  living	  to	  minimize	  the	  pain	  they	  may	  experience	  doing	  these	  tasks	  (Mayes	  &	  Ho,	  n.d.).	  	  Sallam,	  McNeary,	  and	  Chen	  reviewed	  several	  complementary	  and	  alternative	  medicine	  CAM	  treatments,	  including	  electroacupuncture	  and	  transcutaneous-­‐electroacupuncture,	  for	  the	  treatment	  of	  gastrointestinal	  dysmotility,	  a	  common	  cause	  of	  SSc	  pain	  (Sallam,	  McNeary	  &	  Chen,	  2014).	  While	  they	  reported	  that	  larger	  study	  samples	  were	  needed,	  they	  found	  it	  would	  be	  important	  to	  tailor	  the	  treatments	  to	  the	  individual	  patient	  with	  regard	  to	  such	  factors	  as	  duration	  of	  their	  disease	  and	  SSc	  involvement	  (Sallam,	  McNeary	  &	  Chen,	  2014).	  	  	   Another	  possible	  option	  discussed	  in	  the	  literature	  is	  surgery.	  The	  health	  care	  field	  generally	  sees	  surgical	  treatment	  as	  a	  last	  resort,	  to	  be	  used	  only	  after	  all	  other	  medical	  treatments	  have	  failed	  (Momeni	  et	  al.,	  2015).	  	  Momeni	  et	  al.’s	  study	  found	  that	  the	  use	  of	  peripheral	  sympathectomy,	  the	  surgical	  cutting	  of	  a	  sympathetic	  nerve	  or	  removal	  of	  a	  ganglion	  to	  relieve	  a	  condition	  affected	  by	  its	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stimulation,	  relieved	  pain	  in	  92.3%	  of	  patients	  with	  systemic	  sclerosis,	  with	  only	  minor	  complications	  (Momeni	  et	  al.,	  2015).	  They	  stated	  that	  the	  timing	  of	  the	  surgery	  is	  crucial,	  as	  obstructive	  fibrosis	  can	  lead	  to	  arterial	  obliteration,	  lessening	  the	  efficacy	  of	  the	  treatment	  (Momeni	  et	  al.,	  2015).	  Since	  there	  is	  no	  predictable	  timeframe	  for	  any	  of	  the	  effects	  of	  this	  disease,	  early	  and	  constant	  evaluation	  for	  the	  usefulness	  of	  this	  procedure	  is	  warranted	  (Momeni	  et	  al.,	  2015).	  
Expected	  Outcomes	  and	  Lessons	  Learned	  Toward	  a	  Less	  Painful	  Future	  	   It	  would	  seem	  that	  the	  first	  step	  in	  beginning	  to	  effectively	  manage	  pain	  like	  Theresa’s	  is	  to	  develop	  an	  effective	  and	  universal	  tool	  to	  assess	  pain	  that	  is	  specific	  to	  the	  systemic	  sclerosis	  disease	  process.	  Being	  able	  to	  understand	  the	  sources	  and	  extent	  of	  an	  individual’s	  pain	  from	  this	  disease	  is	  crucial	  to	  knowing	  how	  best	  to	  treat	  it.	  Helping	  clinicians	  to	  understand	  also,	  that	  there	  is	  no	  normative	  pain	  experience	  in	  this	  disease,	  that	  everyone’s	  pain	  is	  going	  to	  be	  different	  because	  this	  disease	  affects	  so	  many	  body	  systems	  in	  a	  myriad	  of	  ways,	  will	  also	  be	  a	  necessary	  step	  toward	  having	  effective	  SSc	  pain	  management.	  	   Toward	  that	  end,	  a	  change	  in	  the	  academia	  of	  rheumatologists	  would	  be	  useful,	  so	  as	  to	  include	  training	  in	  disease	  specific	  pain	  management.	  Additionally,	  it	  would	  be	  useful	  to	  include	  a	  more	  significant	  training	  on	  SSc	  in	  general	  medical	  training	  as	  well.	  Kwakkenbos	  et	  al.	  noted	  a	  lack	  of	  rare	  disease	  treatment	  centers;	  thus	  patients	  with	  SSc	  may	  be	  receiving	  treatment	  from	  clinicians	  who	  are	  unfamiliar	  with	  their	  disease	  process	  and	  its	  treatment	  (Kwakkenbos	  et	  al.,	  2013).	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   In	  hopes	  of	  solving	  the	  problems	  listed	  above,	  Kwakkenbos	  and	  her	  team	  have	  created	  The	  Scleroderma	  Patient-­‐Centered	  Intervention	  Network	  (SPIN),	  funded	  by	  the	  Canadian	  Institutes	  of	  Health	  Research	  (Kwakkenbos	  et	  al.,	  2013).	  SPIN	  is	  an	  international	  group	  of	  providers,	  researchers,	  and	  patient	  advocacy	  groups	  created	  in	  order	  to	  develop	  and	  disseminate	  evidence-­‐based	  practices	  for	  the	  treatment	  of	  scleroderma	  (Kwakkenbos	  et	  al.,	  2013).	  	  The	  interventions	  developed	  will	  utilize	  the	  assistance	  of	  the	  patient	  cohort,	  and	  will	  be	  available	  in	  a	  self-­‐guided	  online	  format	  (Kwakkenbos	  et	  al.,	  2013).	  Unfortunately,	  none	  of	  the	  four	  initial	  intervention	  goals	  of	  SPIN	  address	  pain	  specifically,	  but	  they	  do	  address	  issues	  which	  could	  conceivably	  result	  in	  better	  pain	  management	  for	  people	  with	  SSc,	  such	  as	  “physical	  and	  occupational	  therapy	  for	  hands”	  (Kwakkenbos	  et	  al.,	  2013).	  	  	  	   The	  concept	  of	  improving	  self-­‐efficacy	  in	  people	  with	  SSc	  has	  also	  been	  addressed	  as	  a	  great	  need	  in	  the	  literature,	  and	  could	  help	  with	  pain	  management.	  Buck,	  Poole,	  and	  Mendelson	  examined	  self-­‐efficacy	  in	  the	  SSc	  population	  and	  found	  that,	  due	  to	  a	  significant	  lack	  of	  existing	  information	  on	  the	  disease,	  people	  with	  scleroderma	  have	  had	  to	  become	  their	  own	  advocates	  (Buck,	  Poole	  &	  Mendelson,	  2010).	  	  But	  their	  study	  found	  that	  higher	  rates	  of	  pain	  equated	  to	  lower	  rates	  of	  self-­‐efficacy	  (Buck,	  Poole	  &	  Mendelson,	  2010).	  	  It	  would	  then	  follow	  that	  assisting	  patients	  with	  developing	  self-­‐efficacy,	  particularly	  through	  the	  use	  of	  self-­‐management	  programs,	  would	  help	  decrease	  their	  pain	  levels.	  	  	   Poole	  and	  Mendelson	  followed	  up	  by	  developing	  a	  mail-­‐delivered,	  print-­‐format	  self-­‐management	  program	  specifically	  created	  for	  people	  with	  systemic	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sclerosis	  (Poole,	  Skipper	  &	  Mendelson,	  2013).	  They	  found	  that	  no	  other	  current	  chronic	  disease	  management	  program	  existed	  for	  people	  with	  SSc	  (Poole,	  Skipper	  &	  Mendelson,	  2013).	  Their	  program	  consisted	  of	  a	  workbook	  (spiral	  bound	  which	  they	  found	  worked	  better	  for	  people	  suffering	  from	  sclerodactyly)	  and	  a	  DVD,	  which	  contained	  exercises	  for	  the	  face,	  mouth,	  hand,	  arm,	  and	  leg	  (all	  of	  which	  are	  sources	  of	  pain	  in	  SSc).	  	  The	  conclusion	  of	  their	  study	  found	  that	  use	  of	  the	  program	  caused	  pain	  levels	  to	  decrease,	  along	  with	  depression	  and	  fatigue	  (Poole,	  Skipper	  &	  Mendelson,	  2013).	  Additionally,	  self-­‐efficacy	  for	  controlling	  pain	  increased,	  as	  did	  hand	  function	  (Poole,	  Skipper	  &	  Mendelson,	  2013).	  In	  addition	  to	  helping	  patients	  with	  SSc,	  it	  was	  noted	  that	  the	  content	  of	  the	  program	  might	  also	  be	  of	  value	  in	  educating	  clinicians	  treating	  these	  patients	  (Poole,	  Skipper	  &	  Mendelson,	  2013).	  	   Because	  there	  is	  currently	  a	  lack	  of	  evidenced-­‐based	  self-­‐efficacy	  interventions	  for	  patients	  with	  SSc,	  it	  may	  be	  helpful	  for	  patients	  to	  use	  some	  advocacy	  techniques	  to	  assist	  with	  building	  their	  own	  self-­‐efficacy.	  Keeping	  a	  pain	  journal,	  to	  note	  their	  daily	  occurrences	  of	  pain,	  the	  quality	  and	  quantity	  of	  the	  pain,	  and	  what	  caused	  it,	  might	  be	  helpful	  for	  patients	  with	  SSc	  to	  give	  to	  their	  primary	  care	  providers.	  If	  their	  providers	  are	  not	  regularly	  assessing	  pain,	  these	  journals	  would	  be	  a	  way	  for	  patients	  with	  SSc	  to	  provide	  subjective	  and	  objective	  data	  to	  demonstrate	  their	  need	  for	  pain	  management.	  Additionally,	  patients	  with	  SSc	  should	  always	  carry	  a	  list	  of	  their	  medications	  on	  them	  at	  all	  times,	  and	  ensure	  that	  whomever	  is	  treating	  them	  has	  the	  most	  updated	  list	  possible.	  It	  is	  also	  helpful	  to	  have	  a	  health	  care	  power	  of	  attorney	  to	  serve	  as	  an	  advocate	  for	  the	  patient’s	  pain	  management	  needs	  when	  the	  patient	  is	  unable	  to	  do	  so	  themselves.	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   The	  organization	  EULAR,	  the	  European	  League	  Against	  Rheumatism,	  created	  a	  list	  of	  evidenced-­‐based	  recommendations	  for	  rheumatologists	  for	  the	  pharmacological	  treatment	  of	  systemic	  sclerosis,	  which	  are	  now	  widely	  accepted	  (Kowal-­‐Bielecka	  et	  al.,	  2009).	  However,	  nowhere	  in	  their	  guidelines	  is	  there	  any	  mention	  of	  pharmacological	  pain	  management.	  Evidenced-­‐based	  protocols	  for	  the	  practice	  of	  pain	  treatment	  for	  the	  varying	  types	  of	  pain	  present	  in	  SSc	  need	  to	  be	  developed.	  Further	  testing	  needs	  to	  be	  conducted	  into	  the	  long-­‐term	  use	  of	  oxycodone	  as	  an	  effective	  treatment,	  and	  guidelines	  for	  its	  use	  need	  to	  be	  established.	  Other	  medications,	  such	  as	  N-­‐acetylcysteine	  for	  the	  treatment	  of	  Reynaud’s	  Phenomenon	  and	  digital	  ulcers,	  need	  to	  be	  evaluated	  in	  larger	  cohort	  studies	  (Rosato	  et	  al.,	  2009).	  	   Kwakkenbos	  et	  al.	  presented	  a	  case	  study	  of	  the	  use	  of	  Cognitive	  Behavioral	  Therapy	  to	  target	  the	  fear	  of	  progression	  of	  systemic	  sclerosis	  symptoms,	  as	  was	  previously	  mentioned	  (Kwakkenbos	  et	  al.,	  2014).	  Assessing	  for	  and	  treating	  the	  mental	  health	  of	  patients	  with	  SSc	  is	  crucial	  to	  helping	  them	  manage	  their	  pain.	  	  Implications	  for	  Nursing	  	   While	  primary	  care	  from	  a	  rheumatologist	  for	  patients	  with	  SSc	  is	  essential,	  holistic	  nursing	  care	  is	  crucial	  in	  successfully	  managing	  pain	  from	  SSc.	  There	  is	  a	  significant	  amount	  of	  education	  that	  needs	  to	  be	  provided,	  all	  of	  which	  is	  important	  for	  improving	  the	  self-­‐efficacy	  of	  these	  patients.	  Schouffer	  et	  al.	  found	  that	  a	  majority	  of	  patients	  with	  SSc	  had	  significant	  unmet	  information	  needs	  regarding	  both	  their	  physical	  and	  mental	  treatment	  (Schouffer	  et	  al.,	  2011).	  	  In	  a	  Dutch	  study,	  information	  needs	  actually	  ranked	  highest	  on	  a	  four-­‐point	  Likert	  scale,	  with	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medication	  usage	  and	  dealing	  with	  pain	  following	  closely	  behind	  (Schouffer	  et	  al.,	  2011).	  	  Nurses	  can	  be	  the	  information	  source	  for	  these	  patients:	  teaching	  them	  about	  staying	  warm	  to	  help	  minimize	  the	  complications	  from	  Raynaud’s,	  constantly	  drinking	  fluids	  to	  combat	  the	  problems	  associated	  with	  Sjogren’s	  syndrome,	  seeking	  out	  massage,	  acupuncture,	  and	  other	  alternative	  treatments	  to	  help	  with	  the	  stiffness	  from	  muscle	  contractures.	  	  	   Nurses	  should	  also	  be	  acting	  as	  advocates	  for	  patients	  with	  SSc.	  Constant	  assessment	  of	  the	  patient’s	  current	  physical	  and	  mental	  condition,	  and	  knowing	  the	  symptoms	  of	  SSc	  for	  which	  one	  should	  be	  looking,	  will	  provide	  the	  nurse	  with	  the	  necessary	  information	  to	  accurately	  provide	  care	  for	  these	  patients	  (Furst,	  2015).	  Discussing	  pain	  and	  pain	  management	  with	  patients	  with	  SSc	  on	  an	  ongoing	  basis	  will	  help	  nurses	  better	  advocate	  for	  their	  patients	  with	  providers.	  Advocacy	  here	  also	  needs	  to	  focus	  on	  the	  patients’	  psychosocial	  needs	  (Furst,	  2015).	  Building	  a	  trusting	  relationship	  with	  your	  patients	  with	  SSc	  may	  help	  them	  feel	  comfortable	  enough	  to	  disclose	  issues	  with	  depression	  and	  anxiety	  that	  they	  may	  be	  facing	  (Furst,	  2015).	  Given	  the	  link	  between	  pain	  and	  depression/anxiety,	  it	  is	  important	  for	  the	  nurse	  to	  readily	  identify	  if	  a	  patient	  is	  experiencing	  such	  issues,	  in	  order	  to	  assist	  them	  in	  seeking	  treatment,	  thereby	  contributing	  to	  their	  pain	  management.	  	   Kwakkenbos	  et	  al.	  also	  suggested	  the	  use	  of	  a	  specialized	  nurse,	  acting	  as	  part	  of	  the	  interdisciplinary	  SSc	  team.	  This	  nurse’s	  main	  goals	  would	  be	  medication	  management,	  ensuring	  an	  adequate	  balance	  between	  daily	  activities	  and	  appropriate	  rest,	  and	  managing	  and	  providing	  successful	  skincare	  for	  the	  scleroderma	  patient	  (Kwakkenbos	  et	  al.,	  2014).	  While	  specialized	  nursing	  would	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definitely	  be	  a	  benefit	  to	  decreasing	  the	  pain	  experienced	  by	  patients	  with	  SSc,	  given	  what	  is	  known	  about	  the	  disease,	  and	  subsequent	  pain	  from	  it,	  affecting	  every	  aspect	  of	  the	  patient,	  a	  holistic	  nursing	  approach	  is	  also	  needed.	  Providing	  education,	  social	  and	  emotional	  support,	  and	  acting	  as	  advocates	  for	  appropriate	  and	  effective	  management	  of	  pain	  are	  all	  necessary	  pieces	  of	  the	  nursing	  plan	  of	  care	  for	  patients	  with	  scleroderma.	  
Conclusions	  	   Pain	  needs	  to	  be	  assessed	  during	  the	  initial	  visit	  with	  the	  rheumatologist,	  and	  at	  all	  subsequent	  visits	  thereafter,	  using	  a	  pain	  assessment	  tool	  specifically	  designed	  not	  just	  for	  scleroderma,	  but	  for	  the	  subset	  of	  scleroderma	  the	  patient	  has,	  i.e.	  limited	  or	  diffuse.	  Management	  of	  the	  multifocal,	  chronic	  pain	  associated	  with	  this	  disease	  needs	  to	  become	  one	  of	  the	  main	  treatment	  goals	  in	  planning	  care	  for	  patients	  with	  SSc.	  Dealing	  with	  the	  physical,	  mental,	  and	  emotional	  effects	  of	  scleroderma,	  by	  looking	  at	  the	  disease	  through	  a	  holistic	  approach,	  and	  utilizing	  a	  multidisciplinary	  team	  (comprised	  of	  rheumatologists,	  primary	  care	  providers,	  pain	  management	  providers,	  occupational	  therapists,	  physical	  therapists,	  psychologists,	  psychiatrists,	  pharmacists,	  nursing	  staff,	  and	  CAM	  providers)	  would	  provide	  the	  most	  comprehensive	  approach	  possible	  to	  the	  treatment	  of	  pain	  in	  this	  disease.	  Theresa	  spent	  the	  majority	  of	  the	  last	  11	  years	  of	  her	  life	  in	  pain.	  Had	  there	  been	  evidenced-­‐based	  pain	  management	  interventions	  in	  place	  for	  treatment	  of	  scleroderma	  pain,	  the	  quality	  of	  those	  11	  years	  most	  likely	  would	  have	  been	  significantly	  improved.	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